ERBB2 and bile duct carcinoma: HER2 overexpression identified by immunohistochemistry is identified in 50% of bile duct carcinomas (5% in extrahepatic bile duct carcinomas, 16% in gallbladder carcinomas, and 12% in ampulla of Vater carcinomas).